An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment
Author:
Liu Jie,
Han Xiao,
Hu Xiufeng,
He Yuange,
Shao Yijia,
Yang Yanyan,
Wang Kai,
Zhao YanqiuORCID
Subject
Multidisciplinary